

Publikationen 2022

1. Felten L, Leuchten N, Aringer M. Glucocorticoid dosing and relapses in giant cell arteritis-a single center cohort study. **Rheumatology (Oxford)** 2022; 61: 1997-2005.
2. Kiltz U, Buschhorn-Milberger V, Albrecht K, Lakomek HJ, Lorenz HM, Rudwaleit M, Schneider M, Schulze-Koops H, Aringer M, Hasenbring MI, Herzer P, von Hinüber U, Krüger K, Lauterbach A, Manger B, Oltman R, Schuch F, Schmale-Grede R, Späthling-Mestekemper S, Zinke S, Braun J. Entwicklung von Qualitätsstandards für die Versorgung von Patient*innen mit rheumatoider Arthritis zur Anwendung in Deutschland. **Z Rheumatol** 2022; 81: 744-759.
3. Stone JH, Spotswood H, Unizony SH, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Bao M. New-onset versus relapsing giant cell arteritis treated with tocilizumab: 3-year results from a randomized controlled trial and extension. **Rheumatology (Oxford)** 2022; 61: 2915-2922.
4. Specker C, Aringer M, Burmester GR, Killy B, Hofmann MW, Kellner H, Moosig F, Tony HP, Fliedner G. The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age. **Clin Exp Rheumatol** 2022; 40: 1657-1665.
5. Matteson EL, Kelly C, Distler JHW, Hoffmann-Vold AM, Seibold JR, Mittoo S, Dellaripa PF, Aringer M, Pope J, Distler O, James A, Schlenker-Herceg R, Stowasser S, Quaresma M, Flaherty KR; INBUILD trial investigators. Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD trial. **Arthritis Rheumatol** 2022; 74: 1039-1047.
6. Guttmann A, Denvir B, Aringer M, Buyon JP, Belmont HM, Sahl S, Salmon JE, Askanase A, Bathon JM, Geraldino-Pardilla L, Ali Y, Ginzler EM, Putterman C, Gordon C, Helmick CG, Parton H, Izmirly PM. Evaluation of the European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus in a population based registry. **Arthritis Care Res (Hoboken)** 2022; May 31 Epub.
7. Thiele K, Albrecht K, Zink A, Aringer M, Karberg K, Späthling-Mestekemper S, von Hinüber U, Callhoff J. Is the Rheumatoid Arthritis Impact of Disease (RAID) score a meaningful instrument for other inflammatory rheumatic diseases? A cross-sectional analysis of data from the German National Database. **RMD Open** 2022; 8: e002342.

8. Aringer M. Who will respond to type I interferon blockade in SLE? **Lancet Rheumatol** 2022; 4: e234-e236.
9. Aringer M, Costenbader K, Johnson SR. Assessing the EULAR/ACR classification criteria for patients with systemic lupus erythematosus. **Expert Rev Clin Immunol** 2022; 18: 135-144.
10. Aringer M, Alarcón-Riquelme ME, Clowse M, Pons-Estel GJ, Vital EM, Dall'Era M. A glimpse into the future of systemic lupus erythematosus. **Ther Adv Musculoskelet Dis** 2022; 14: 1759720X221086719. Impact factor 3,625.
11. Aringer M, Hugo C. Sollte HCQ bei Dialysepflicht bei SLE eingesetzt werden? **Z Rheumatol** 2022; 81: 507-508.
12. Aringer M, Costenbader K, Dörner T, Johnson SR. Advances in SLE classification criteria. **J Autoimmun** 2022; 132: 102845. Impact factor 14,511.
13. Kiltz U, Buschhorn-Milberger V, Albrecht K, Lakomek HJ, Lorenz HM, Rudwaleit M, Schneider M, Schulze-Koops H, Aringer M, Hasenbring MI, Herzer P, von Hinüber U, Krüger K, Lauterbach A, Manger B, Oltman R, Schuch F, Schmale-Grede R, Späthling-Mestekemper S, Zinke S, Braun J. Entwicklung von Qualitätsstandards für die Versorgung von Patient*innen mit rheumatoider Arthritis zur Anwendung in Deutschland. **Z Rheumatol** 2022; 81: 744-759.
14. Koehm M, Foldenauer AC, Rossmann T, Alten R, Aringer M, Backhaus M, Burmester GR, Feist E, Kellner H, Krueger K, Müller-Ladner U, Rubbert-Roth A, Tony HP, Wassenberg S, Burkhardt H, Behrens F. Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA). **J Clin Med** 2022; 11: 7316.
15. Sumpter NA, Takei R, Cadzow M, Topless RKG, Phipps-Green AJ, Murphy R, de Zoysa J, Watson H, Qasim M, Lupi AS, Abhishek A, Andrés M, Crişan TO, Doherty M, Jacobsson L, Janssen M, Jansen TL, Joosten LAB, Kapetanovic M, Lioté F, Matsuo H, McCarthy GM, Perez-Ruiz F, Riches P, Richette P, Roddy E, Stiburkova B, So A, Tausche AK, Torres RJ, Uhlig T, Major TJ, Stamp LK, Dalbeth N, Choi HK, Vazquez AI, Leask MP, Reynolds RJ, Merriman TR. Association of Gout Polygenic Risk Score with Age at Disease Onset and Tophaceous Disease in European and Polynesian Men with Gout. **Arthritis Rheumatol** 2022, Oct 25 Epub.
16. Lenk J, Matthé E, Pillunat LE, Aringer M. Systemischer Lupus erythematosus durch Tumornekrosefaktor-Blocker – Eine seltene Nebenwirkung einer Uveitis-intermedia-Therapie. **Ophthalmologe** 2022; 119: 851-854.
17. Tausche AK. Gicht. **Z Rheumatol** 2022; 81: 400-412.
18. Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, Boumpas DT, Brodin N, Bruce IN, González-Gay MÁ, Jacobsen S, Kerekes G, Marchiori F, Mukhtyar C, Ramos-Casals M, Sattar N, Schreiber K, Sciascia S, Svenungsson E, Szekanecz Z, Tausche AK, Tyndall A, van Halm V, Voskuyl A, Macfarlane GJ, Ward MM, Nurmohamed MT, Tektonidou MG. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases,

including systemic lupus erythematosus and antiphospholipid syndrome. **Ann Rheum Dis** 2022; 81: 768-779.

19. Desideri G, Rajzer M, Gerritsen M, Nurmohamed MT, Giannattasio C, Tausche AK, Borghi C. Effects of intensive urate lowering therapy with febuxostat in comparison with allopurinol on pulse wave velocity in patients with gout and increased cardiovascular risk: the FORWARD study. **Eur Heart J Cardiovasc Pharmacother** 2022; 8: 236-242.